

Serum Leptin Levels and Lipid Profiles in Patients with Allergic Rhinitis and Mild Asthma

F. Erel^a, M. Gulec^a, O. Kartal, Z. Caliskaner^a, S. Ozturk^a, H. Yaman^b,
Y. Kurt^b, E. Gocgeldi^c, F. Ors^d and M. Karaayvaz^a

^aDepartment Internal Medicine & Division of Allergy. ^bDepartment of Biochemistry. ^cDepartment of Public Health. ^dDepartment of Radiology. Gülhane Military Medical Academy and Medical School. Ankara. Turkey.

ABSTRACT

Background: Despite improved understanding of the pathophysiology of allergic rhinitis and asthma, the effect of serum leptin level is still controversial. Only a few studies have been performed to investigate the serum leptin levels in allergic rhinitis and asthma, and contradictory results have been observed.

Objective: We aimed to investigate the association between leptin, lipid profiles and allergic rhinitis and mild asthma, and to determine whether inhaled and/or intranasal steroids affect the leptin levels.

Patients and methods: We studied 43 patients with allergic rhinitis (10 of with mild asthma) (mean age 29.81, range 18-45 yr) and 32 volunteers as a control group (mean age 30.53, range 20-45 yr).

Results: Serum leptin levels in patients were 8.49 ± 10.76 $\mu\text{g/ml}$, and did not differ from volunteers 5.42 ± 6.63 $\mu\text{g/ml}$. ($p > 0.05$). We found a direct link between increased body mass index (BMI) and serum leptin levels ($p = 0.008$). No association was seen between leptin and triglyceride, HDL-cholesterol,

VLDL-cholesterol, eosinophil, total IgE ($p > 0.05$); except for total cholesterol and LDL-cholesterol ($p < 0.05$). Although, no correlation between allergic rhinitis and mild asthma and serum level of leptin was shown, these parameters and age correlations were stronger in female than in male ($p = 0.39$ for male and $p = 0.011$ for female), and also found direct link between increased BMI and sex and patients group ($p = 0.008$ for male and $p = 0.0001$ for female). We also determined that there was no effect of inhaled and/or intranasal steroids statistically on serum leptin levels.

Conclusion: Our data demonstrate that the serum levels of leptin and lipid profiles on allergic rhinitis and mild asthma were not different than those in controls.

Key words: Allergic. Asthma. Leptin. Rhinitis. Steroid. United airway disease.

INTRODUCTION

Leptin, 16-kDa protein hormone, is produced by white adipose tissue. Structurally, it is a member of the IL-6 family of cytokines. Leptin is an anorexigenic peptide that is primarily known for its role as a hypothalamic modulator of food intake, body weight and fat stores¹.

In addition to its effect on the hypothalamus, leptin is a modulator of the immune and proinflammatory responses. Leptin acts directly on T cells where it enhances the production of Th1 cells promoting inflammation^{2,3}. Leptin also plays a significant role in,

Correspondence:

Dr. F. Erel
Gülhane Askeri Tıp Akademisi
Allerjik Hastalıklar BD
06018, Ankara, Türkiye
Fax: + 90-312-304 4139
E-mail: fuatereldr@hotmail.com

e.g., reproductive processes, angiogenesis, hematopoiesis and oxidation of lipids.

On the other hand, leptin had already been shown to be associated with asthma, and there have been reports that asthma and obesity are related⁴⁻⁷. The mechanisms by which leptin may be a risk factor for allergic rhinitis and asthma are not entirely understood, although a few recent studies have addressed this question⁴⁻⁹.

There is a close link between allergic rhinitis and allergic bronchial asthma. The lining of the airway from the nose to the lungs is similar in structure and therefore similarly affected by the allergic process - so what affects the nose also can affect the lungs. And often what happens in one part of the airway has an impact on the other. Although some patients with do not have asthma, inflammatory changes can still be evident in their lower airway. Up to % 30 of allergic rhinitis (AR) patients, with no past history of asthma, will show bronchial hyperreactivity to methacholine¹⁰.

A report from the American Academy of Allergy, Asthma, and Immunology estimated that up to 78 % of patients with asthma have nasal symptoms and 38 % of patients with allergic rhinitis have asthma¹¹. Adequate treatment of rhinitis might positively affect the course of asthma, and worsening of rhinitis was associated with persistence of asthma symptoms¹⁰.

Because of these relations, various researchers, especially in the last ten years, have referred to allergic rhinitis and asthma as allergic united airway disease^{10,12-14} and recently as combined AR and asthma syndrome (CARAS)¹⁵.

Since, AR and asthma are both mediated by similar allergic inflammatory mechanism, we aimed

to evaluate changes of serum leptin concentration and answer the question whether there exists a relationship between leptin levels and allergic rhinitis and asthma or not, and the effect of an inhaler and/or intranasal administered corticosteroid (budesonide) on it.

PATIENTS AND METHODS

This was a prospective study enrolling 43 patients with allergic rhinitis (10 of with mild asthma) (mean age 29.81, range 18-45 yr) and 32 volunteers as a control group (mean age 30.53, range 20-45 yr). All patients and control groups accepted to participate in the study. Patients were recruited during the symptomatic period in GATA Allergy Clinic, Ankara, Turkey.

Demographic characteristics were recorded and body mass index (BMI) values were calculated ($= \text{weight [kg]}/\text{height}^2 \text{ (m}^2\text{)}$) for all patients (table I). After a 12-hour overnight fast, venous blood samples were collected after 10 to 15 minutes of rest to measure serum leptin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), eosinophil and total IgE levels. Samples were centrifuged at 4 °C; serum samples were stored at -70 °C until analysis. Low-density lipoprotein-cholesterol (LDL-C) and very low-density lipoprotein-cholesterol (VLDL-C) values were calculated with the Friedewald formula. The principle of the Friedewald formula is based on two assumptions: Firstly, that since very low-density lipoprotein (VLDL) carries most of the circulating triglycerides, VLDL-C can be estimated reasonably well as TG concentrations divided by constant (i.e. 5 for mg/dL and 2.2 for mmol/L). Secondly, that TC is distributed among the three major lipopro-

Table I

Clinical characteristics of patients and control groups

	Groups	n	Mean	Min-Max	Std. D.	p
Age	Patient	43	29.81	18-45	7.95	0.714
	Control	32	30.53	20-45	8.88	
Gender	Patient	43 (Male: 24; Female: 19)				
	Control	32 (Male: 18; Female: 14)				
Height (cm)	Patient		170.98	149-186	10.76	0.637
	Control		169.81	155-190	10.20	
Weight (kg)	Patient		72.40	49-102	12.46	0.421
	Control		70.03	46-91	12.65	
BMI	Patient		24.75	18.3-36.4	3.90	0.486
	Control		24.15	19.1-36	3.25	

tein subclasses [namely HDL, LDL and VLDL. There are though some limitations as to the calculation of LDL-C according to the LDL-F formula, the two most common being that the patient needs to be fasting for at least 12 hours and that TG levels have to be < 400 mg/dL¹⁶ Serum leptin levels were measured by a commercially available kit (BIOSOURCE LEPTIN EASIA [BioSource Europe S.A., Nivelles, Belgium]) according to the manufacturer's instructions. (Reference interval in healthy lean adult: lean male 2.4 ± 1.1 ng/ml, lean female 6.6 ± 3.0 ng/ml.)

Skin prick tests were performed on the forearms using extracts of grass mix, tree mix, cockroach, mould mix, weed mix, dermatophagoides pteronyssinus, dermatophagoides farinae, dander of dog and cat, negative and positive (histamine) control (Allergo, Stuttgart, Germany). Besides, ultrasonographic examinations performed to evaluate parenchymal changes of liver before and after treatment.

Allergic rhinitis was classified according to the 4 classes of ARIA (mild intermittent, mild persistent, moderate/severe intermittent, moderate/severe persistent), and defined as having a score of 2 or more on a 0 to 3 point scale (0, no symptoms and 3, severe symptoms) regarding to sneezing, itchy nose, running nose, stuffy nose, and eye symptoms¹⁷. All patients received nasal budesonide one month (in daily dose of 400 µg).

Asthma was defined and severity was classified according to GINA guidelines and 10 asthmatic patients were additionally treated with a low dose of inhaled corticosteroids (400 µg inhaled budesonide, daily) and rapid acting β_2 -agonist, if needed¹⁸⁻²⁰. Asthma symptoms, the number of symptom-free days, use of rescue medication were assessed from asthmatic patients during one month and the rate of asthmatic score was determined. Pulmonary function tests such as forced vital capacity (FVC), forced expiratory volume/1 second (FEV₁) and FEV₁/FVC were performed to all patients before and after treatment.

Inclusion Criteria for Study Entry was shown on table II. The University Bioethics Committee approved the study protocol and informed consent was obtained from each patient and volunteer.

Table II

Inclusion criteria for study entry

1. FEV₁ > 80 % of predicted value
2. Nonsmoker
3. No respiratory tract infection or asthma exacerbation within 4 weeks
4. No serious medical illness other than rhinitis and asthma
5. No treatment with corticosteroids within 3 months

Statistical analysis

The statistical analyses were performed using a statistical software package – SPSS for windows, SPSS Inc. USA). Independent samples test statistical analysis was used to compare demographic findings of the subjects. In the analyses of presence of asthma, sex and age differences, comparison of serum leptin levels before and after treatment were used Pearson correlation test.

RESULTS

There were no differences between the two groups (patients and volunteers) with respect to demographic characteristics and laboratory analyses (including pulmonary function test), but clear significant differences were noted concerning the eosinophils, an indicator of allergic inflammation (table III). We found a direct link between increased BMI and serum leptin levels ($p = 0.0001$) (table IV). No association

Table III

Comparisons of groups regarding biochemical analyses and pulmonary function tests

	Groups	Mean	Min-Max	Std. D.	<i>p</i>
LEPTIN	Patient	8.4953	0.20-55.10	10.763	0.158
	Control	5.4187	0.20-36.60	6.626	
Triglyceride	Patient	99.953	26-215	38.965	0.137
	Control	114.250	70-200	43.063	
Cholesterol	Patient	170.186	104-256	40.182	0.777
	Control	172.875	70-200	40.873	
HDL	Patient	51.907	33-76	9.281	0.194
	Control	48.594	28-69	12.613	
LDL	Patient	98.316	41-179	33.955	0.798
	Control	100.306	35-153	31.918	
VLDL	Patient	19.916	5.20-43	7.809	0.057
	Control	23.831	14-40	8.937	
Eosinophil	Patient	3.451	0.06-13	2.826	0.002
	Control	1.693	0.84-5.25	1.213	
Total IgE	Patient	163.847	9.57-1762	284.970	0.190
	Control	87.511	7.38-644	183.264	
FVC	Patient	94.396	68-114	10.130	0.150
	Control	86.312	72-89	17.741	
FEV ₁	Patient	97.079	81-115	11.254	0.863
	Control	96.658	82-118	9.106	
FEV ₁ /FVC	Patient	103.014	88-119	7.389	0.386
	Control	98.9	91-119	29.778	

was seen between leptin and triglyceride, HDL-cholesterol, VLDL-cholesterol, eosinophil, total IgE ($p > 0.05$); except for total cholesterol and LDL-cholesterol ($p < 0.05$) (table IV).

There is no effect to the leptin levels on the severity of allergic rhinitis and asthma existence or not (tables V, VI). Although the allergenic sensitivity seems to be no effect on serum leptin concentrations ($p > 0.05$) (table VII), leptin level is found higher in pollen sensitivity than house dust mite sensitivity after separating from mix group ($p = 0,026$). When distributing the patients by bipartite of BMI (as normal and high weight or obese), the leptin levels were found an increase in high weight or obese ($p = 0.008$) (table VIII). A significant correlation was found between leptin and sex in two groups, in favor of female ($p < 0.05$) (table IX).

Table IV

Association between serum leptin concentrations and biochemical analyses and lung function tests

	LEPTIN Pearson Correlation Sig. (2-tailed)	<i>p</i>
BMI	0.653	0.0001
Triglyceride	0.083	0.598
Cholesterol	0.379	0.012
HDL	0.110	0.483
LDL	0.402	0.008
VLDL	0.079	0.616
Eosinophil	-0.012	0.939
Total IgE	-0.157	0.316
FVC	0.423	0.521
FEV ₁	0.215	0.165
FEV ₁ /FVC	-0.257	0.096

Table V

Serum leptin concentrations according to asthma occurrence or not

		Patient	Mean	Std.D.	<i>p</i>
LEPTIN	Allergic rhinitis without asthma	33	7.90	10.609	0.730
	Allergic rhinitis with asthma	10	10.45	11.613	

Table VI

Serum leptin concentrations according to the severity of allergic rhinitis

	Severity of Allergic Rhinitis	Patient	Mean	Std.D.	<i>p</i>
LEPTIN	Mild intermittent	14	5.836	7.157	0.175
	Severe intermittent	10	8.37	7.494	
	Mild persistent	9	17.367	18.016	
	Severe persistent	10	4.36	3.631	

Table VII

Association between serum leptin concentrations and allergenic status

		Patient	Mean	Std.D.	<i>p</i>
LEPTIN	Pollen sensitivity	20 (% 47)	10.78	13.245	0.102
	House dust mite sensitivity	6 (% 14)	2.133	1.648	
	Mixed sensitivity	17 (% 39)	8.053	8.542	

Table VIII

Association between serum leptin concentrations and BMI

	BMI	Patient	Mean	Std.D.	<i>p</i>
LEPTIN	Normal (< 25)	27	18.09	5.17	0.008
	High weight or obese (≥ 25.0)	16	26.82	14.106	

Table IX

Serum leptin concentrations relation to gender

		Sex	N	Mean	Std. D.	p
LEPTIN	Patient	Male	24	2.238	1.631	0.0001
		Female	19	16.400	12.195	
	Control	Male	18	2.333	1.572	
		Female	14	9.385	8.445	

Table X

Correlation between sex, BMI and serum leptin levels

	Sex	LEPTIN		p
		Pearson	Correlation Sig. (2-tailed)	
Age	Male	0.182	0.394	
	Female	0.568	0.011	
BMI	Male	0.525	0.008	
	Female	0.877	0.0001	

Table XI

Association between serum leptin concentrations and symptoms

	Symptoms	p
LEPTIN	Eye symptoms	0.327
	Sneezing	0.282
	Rhinorrea	0.293
	Nasal itching	0.922
	Nasal congestion	0.327
	Dyspnea	0.871
	Cough	0.501
	Wheezing	0.636
	Limitations of activities	0.823
	Nocturnal symptoms/awakening	0.642

Although, no correlation between allergic rhinitis and mild asthma and serum levels of leptin was shown, these parameters and age correlations were stronger in female than in male, particularly in pre-menopausal women ($p = 0.39$ for male and $p = 0.011$ for female), and also found direct link between increased BMI and sex in patient group ($p = 0.008$ for male and $p = 0.0001$ for female) (table X). Serum leptin level distribution related to age and BMI were shown in graphic 1 and 2. There was no association between serum leptin level and patient symptoms (table XI).




Figure 1.—Serum leptin level distribution related to age.




Figure 2.—Serum leptin level distribution related to BMI.

We also determined that there was no effect of intranasal and/or inhaled steroids statistically on serum leptin levels (table XII). It was shown that while asthma score was improving with inhaled and intranasal steroids in allergic rhinitis and mild asthma ($p = 0.017$), serum leptin level was a little decreased, but not found statistically meaningful ($p = 0.735$) (table XIII). Lastly, all of ultrasonographic examinations (parenchymal changes of liver) were found normal.

Table XII**The effect of budesonide on serum leptin concentrations in all patients**

	Treatment	Mean	Std. D.	p
LEPTIN	Before	9.268	12.504	0.150
	After	7.732	9.625	

Table XIII**The effect of treatment on serum leptin concentrations and asthma score in combined disease**

	Treatment	Mean	Std. D.	p
LEPTIN	Before	10.328	12.491	0.735
	After	8.414	9.877	
ASTHMA SCORE*	Before	13.857	4.413	0.017
	After	21.571	3.994	

* < 20 Uncontrolled.
20-24 Partly controlled.
25 Controlled.

DISCUSSION

Our results indicate that the serum leptin levels in allergic rhinitis and mild asthma are similar to normal groups. Our results also indicate that leptin levels show stronger correlation with BMI, particularly in pre-menopausal women. This result is concordant with literature^{5,6,21}.

We found a significant positive correlation between serum leptin concentrations, cholesterol and LDL. A similar association between leptin levels and cholesterol and triglycerides was observed by Bedir et al. in healthy men²².

Previous studies have demonstrated that, increases in BMI and consequently obesity, have been associated with increased prevalence of asthma. But the mechanisms of this association are not fully understood^{4,5,23}.

Some authors declared that, leptin shares structural and functional homology with IL-6 and it may be directly involved in the regulation of the humoral inflammatory response, stimulating the pro-inflammatory Th1 cytokine pathway and suppressing Th2 cytokine production^{7,24-29}. In other words, leptin influences cytokine production from T lymphocytes, generally switching the phenotype toward a TH1 response³⁰. It's known that leptin stimulates the release of proinflammatory cytokines such as interleukin-6, interferon- γ and tumor necrosis factor from

the adipose tissue and promotes Th1 immune responses, consequently²⁹.

When we look at the mechanism of allergy, we can see that Th2 cells are responsible for allergic immune responses that they preferentially produce the cytokines IL-4 (that promotes IgE production and inhibits Th1), IL-5 (a growth and differentiation factor for eosinophils) and IL-13 (involved among other pro-allergenic processes in the bronchial tissue re-modulation that occurs in asthma). On the other hand, Th1 cells produce interferon- γ , and IL-2, which inhibit Th2 lymphocytes in experimental models such as in vitro cell cultures³⁰. Actually, a shift from Th2-polarized immune response toward Th1-oriented pattern has been reported after SIT^{30,31}. As a result, leptin may not be involved in allergic pathway, unlike obesity. Our results show the concordant to this situation. On the contrary to our results, some literatures support the hypothesis that leptin plays a key role in allergic process^{5,8,9}.

Systemic administration of exogenous glucocorticoids has been found to increase circulating leptin levels³². But, nasal and/or inhaled budesonide up to 800 micrograms per day does not influence circulating leptin levels. This result is also concordant with literature³³.

These results indicate that, the effect of leptin on allergic rhinitis and mild asthma was still unclear and to explain these mechanistic pathways need further large studies.

REFERENCES

- Otero M, Lago R, Gomez R, et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. *Rheumatology* 2006;45:944-50.
- Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. *Hepatology* 2005;42:880-5.
- Matarese G. Leptin and the immune system: how nutritional status influences the immune response. *Eur Cytokine Netw* 2000;11:7-14.
- Shore SA, Fredberg JJ. Obesity, smooth muscle, and airway hyperresponsiveness. *J Allergy Clin Immunol* 2005;115:925-7.
- Matsuda K, Nishi Y, Okamoto Y, Kojima M, Matsuishi T. Ghrelin and leptin: A link between obesity and allergy? *J Allergy Clin Immunol* 2006;117:705-6.
- Sood A, Ford ES, Camargo CA. Association between leptin and asthma in adults. *Thorax* 2006;61:300-5.
- Mai X-M, Böttcher MF, Leijon I. Leptin and asthma in overweight children at 12 years of age. *Pediatr Allergy Immunol* 2004;15:523-30.
- Guler N, Kirerleri E, Ones U, Tamay Z, Salmayenli N, Darendeliler F. Leptin: does it have any role in childhood asthma? *J Allergy Clin Immunol* 2004;114:254-9.
- Unal M, Eskandari G, Muslu N, Pata YS, Akbas Y. Serum leptin levels in patients with allergic rhinitis. *Otolaryngol Head Neck Surg* 2006;134:331-3.

10. Taramarcaz P, Gibson PG. The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome. *Clin Exp Allergy* 2004;34:1883-9.
11. The Allergy Report. Overview of allergic diseases: diagnosis, management, and barriers to care. Vol 1. Milwaukee: American Academy of Allergy, Asthma, and Immunology, 2000.
12. Leynaert B, Neukirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. *J Allergy Clin Immunol* 2000;106:201-5.
13. Bugiani M, Carosso A, Migliore E, et al. Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. *Allergy* 2005;60:165-70.
14. Koh YY, Kim CK. The development of asthma in patients with allergic rhinitis. *Curr Opin Allergy Clin Immunol* 2003;3:159-64.
15. Passalacqua G, Canonica GW. Impact of rhinitis on airway inflammation: biological and therapeutic implications. *Respir Res* 2001;2:320-3.
16. Gazi I, Tsimihodimos V, Filippatos TD, et al. LDL cholesterol estimation in patients with the metabolic syndrome. *Lipids Health Dis* 2006;5:8.
17. Bousquet J, Neukirch F, Bousquet PJ. Severity and impairment of allergic rhinitis in patients consulting in primary care. *J Allergy Clin Immunol* 2006;117:158-62.
18. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;108:147-334.
19. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention NIH Pub. No 02-3659, January 1995. Updated 2005. [Cited 2006 Oct 24]. Available from: www.ginaasthma.com
20. Bousquet J, Clark TJH, Hurd S, et al. GINA guidelines on asthma and beyond. *Allergy* 2007;62:102-12.
21. Doniec Z, Pierzchala-Koziec K, Tomalak W, et al. Serum level of leptin and neuropeptide Y in children with mild asthma. *Pneumonol Alergol Pol* 2004;72:9-13.
22. Bedir A, Topbaş M, Tanyeri F, Alvir M, Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. *Jpn Heart J* 2003;44:527-36.
23. Tantisira KG, Litonjua AA, Weiss ST, Fuhlbrigge AL. Association of body mass with pulmonary function in the Childhood Asthma Management Program. *Thorax* 2003;58:1036-41.
24. Wanamethee SG, Tchernova J, Whincup P et al. Plasma leptin: Associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. *Atherosclerosis* 2007;191:418-26.
25. Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature* 1998;394:897-901.
26. Lord GM. Leptin as a proinflammatory cytokine. *Contrib Nephrol* 2006;151:151-64.
27. Bernotiene E, Palmer G, Gabay C. The role of leptin in innate and adaptive immune responses. *Arthritis Res Ther* 2006;8:217.
28. Shore SA, Schwartzman IN, Mellema MS, et al. Effect of leptin on allergic airway responses in mice. *J Allergy Clin Immunol* 2005;115:103-9.
29. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol* 2005;115:911-9.
30. Jayasekera NP, Toma TP, Williams A, Rajakulasingam K. Mechanisms of immunotherapy in allergic rhinitis. *Biomed Pharmacother* 2007;61:29-33.
31. Erel F, Karaayvaz M, Çalışkaner Z, et al. Effect of allergen immunotherapy on the nasal mucosa in patient with allergic rhinitis. *J Invest Allergol Clin Immunol* 2000;10:14-19.
32. Larsson H, Ahren B. Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. *J Clin Endocrinol Metab* 1996;81:4428-32.
33. Heuck C, Wolthers OD. Serum leptin in children with asthma treated with inhaled budesonide. *Respir Med* 1999;93:268-71.